Nature Reviews Cardiology

Article	Citations
COVID-19 and the cardiovascular system	2174
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives	921
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions	552
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective	546
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension	476
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control	353
T cell subsets and functions in atherosclerosis	352
Environmental determinants of cardiovascular disease: lessons learned from air pollution	343
Interplay between inflammation and thrombosis in cardiovascular pathology	326
Evaluation and management of heart failure with preserved ejection fraction	321
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia	321
Smart wearable devices in cardiovascular care: where we are and how to move forward	305
PPAR control of metabolism and cardiovascular functions	285
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management	284
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation	279
Global epidemiology of dyslipidaemias	275
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	268
Cardiac natriuretic peptides	253
Pathophysiology of sepsis-induced cardiomyopathy	227
Native and bioengineered extracellular vesicles for cardiovascular therapeutics	220
Epidemiology of cardiovascular disease in Europe	219
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	217
Global epidemiology of valvular heart disease	207
Transportation noise pollution and cardiovascular disease	204
Self-powered cardiovascular electronic devices and systems	198

Cellular and molecular pathobiology of heart failure with preserved ejection fraction	186
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6	177
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	172
Single-cell RNA sequencing in cardiovascular development, disease and medicine	167
Cardiovascular effects and safety of (non-aspirin) NSAIDs	165
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis	164
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms	161
Ceramides and other sphingolipids as drivers of cardiovascular disease	154
Cardiovascular disease in patients with severe mental illness	150
Heart failure with mid-range or mildly reduced ejection fraction	147
Epicardial adipose tissue in contemporary cardiology	146
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes	141
The role of cardiac rehabilitation in improving cardiovascular outcomes	140
Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment	138
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging	135
Systems biology in cardiovascular disease: a multiomics approach	134
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity	124
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches	123
Lifestyle interventions for the prevention and treatment of hypertension	121
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	115
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy	113
Epidemiology of the inherited cardiomyopathies	112
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management	111
Sit less and move more for cardiovascular health: emerging insights and opportunities	111
Optical coherence tomography in coronary atherosclerosis assessment and intervention	104
Pregnancy and cardiovascular disease	103
Vascular toxic effects of cancer therapies	98
Genomics of hypertension: the road to precision medicine	97
Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target	95
Cardiac optogenetics: a decade of enlightenment	95
High-density lipoproteins, reverse cholesterol transport and atherogenesis	88
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	85
Apolipoproteins in vascular biology and atherosclerotic disease	84
Genomic frontiers in congenital heart disease	82
Catheter ablation for atrial fibrillation: current indications and evolving technologies	81
The role of cellular senescence in cardiac disease: basic biology and clinical relevance	81
Blood pressure and its variability: classic and novel measurement techniques	80
Transforming growth factor-β in myocardial disease	80
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes	78
Device-based therapies for arterial hypertension	76
Cardiovascular risks of climate change	73
Applications of artificial intelligence in cardiovascular imaging	72
Cardiac involvement in the long-term implications of COVID-19	70
Climate change and cardiovascular disease: implications for global health	70
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19	70
Bleeding avoidance strategies in percutaneous coronary intervention	66
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	66
Myocardial stunning and hibernation revisited	65
Mechanisms and consequences of endothelial cell senescence	63
Update on the pathophysiology and medical treatment of peripheral artery disease	63

Social determinants of atrial fibrillation	62
Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions	62
RNA-targeting and gene editing therapies for transthyretin amyloidosis	61
The role of mitochondrial fission in cardiovascular health and disease	60
Sulfide regulation of cardiovascular function in health and disease	60
Vascular endothelial cell development and diversity	59
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	57
Branched-chain amino acids in cardiovascular disease	57
Clinical utility of polygenic risk scores for coronary artery disease	53
Immune cell profiling in atherosclerosis: role in research and precision medicine	52
The evolving cardiac lymphatic vasculature in development, repair and regeneration	52
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	51
A fresh look at coronary microembolization	51
Targeted delivery of therapeutic agents to the heart	50
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications	50
Epidemiology and prevention of venous thromboembolism	50
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs	47
Pharmacogenetics to guide cardiovascular drug therapy	47
Epidemiology and modifiable risk factors for atrial fibrillation	45
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies	45
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	45
Obesity and the risk of cardiometabolic diseases	44
Prevention of atherosclerosis from childhood	44
The health digital twin: advancing precision cardiovascular medicine	44
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	44
The effects of endurance exercise on the heart: panacea or poison?	43
Targeting the sarcomere in inherited cardiomyopathies	41
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management	40
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia	38
Electroimmunology and cardiac arrhythmia	37
The COVID-19 pandemic: a catalyst to improve clinical trials	36
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism	36
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	36
Increasing representation and diversity in cardiovascular clinical trial populations	34
Coronary vessel formation in development and disease: mechanisms and insights for therapy	34
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing	34
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	34
Stroke prevention strategies in high-risk patients with atrial fibrillation	34
Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities	33
Towards precision medicine in heart failure	33
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	32
Remote monitoring and digital health tools in CVD management	32
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets	32
Obstructive sleep apnoea heterogeneity and cardiovascular disease	31
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes	30
Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options	29
The microtubule cytoskeleton in cardiac mechanics and heart failure	29
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention	29
Mechanisms by which angiotensin-receptor blockers increase ACE2 levels	29
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	29
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research	28
Hallmarks of cardiovascular ageing	28
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease	27
The oral microbiome in the pathophysiology of cardiovascular disease	26
Macrophages in cardiac remodelling after myocardial infarction	26
Cardiac fibroblasts and mechanosensation in heart development, health and disease	25
Improving clinical practice guidelines with implementation science	24
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome	23
Reduced hospital admissions for ACS — more collateral damage from COVID-19	23
Temporary mechanical circulatory support devices: practical considerations for all stakeholders	22
Effects of fatty acids on T cell function: role in atherosclerosis	22
A change of heart: new roles for cilia in cardiac development and disease	22
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer	22
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure	21
The need for increased pragmatism in cardiovascular clinical trials	21
Reply to: ‘Interaction between RAAS inhibitors and ACE2 in the context of COVID-19’	21
Single-cell transcriptomics for the assessment of cardiac disease	21
The contribution of the exposome to the burden of cardiovascular disease	21
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	21
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease	20
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	20
Flow-induced reprogramming of endothelial cells in atherosclerosis	20
Pathophysiology and risk factors of peripartum cardiomyopathy	20
Plastics and cardiovascular disease	19
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease	19
The use of new CRISPR tools in cardiovascular research and medicine	19
Calcific aortic valve disease: mechanisms, prevention and treatment	18
Diversity 4.0 in the cardiovascular health-care workforce	18
Genetics and mechanisms of thoracic aortic disease	18
Long COVID and cardiovascular disease: a learning health system approach	17

Clarification of the definition of hypoplastic left heart syndrome	17
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	17
Hypertension in China: epidemiology and treatment initiatives	17
RAAS inhibitors do not increase the risk of COVID-19	16
Non-hyperaemic coronary pressure measurements to guide coronary interventions	16
Genomic enhancers in cardiac development and disease	16
PCSK9-targeted therapies: present and future approaches	16
Interventional therapies for pulmonary embolism	15
Developing a vaccine against atherosclerosis	15
Cardiovascular health and disease in migrant populations: a call to action	14
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?	14
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death	14
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	14
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group	14
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention	13
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges	13
Mechanisms of ryanodine receptor 2 dysfunction in heart failure	13
A pathophysiological compass to personalize antianginal drug treatment	12
The role of aldehyde dehydrogenase 2 in cardiovascular disease	12
Nanotherapeutics for cardiovascular disease	11
The ongoing quest for the first total artificial heart as destination therapy	11
RNA modifications in cardiovascular health and disease	10
A role for lipophagy in atherosclerosis	10
Novel gut microbiota-derived metabolite promotes platelet thrombosis via adrenergic receptor signalling	10
Strategies to prevent burnout in the cardiovascular health-care workforce	10
Oxidation of miRNAs by ROS leads to cardiac hypertrophy	10
Inhibiting fatty acid oxidation promotes cardiomyocyte proliferation	10
The future of cardiac xenotransplantation	9
Global epidemiology of acute coronary syndromes	9
Current and future applications of virtual reality technology for cardiac interventions	9
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thro	8
Trained immunity in atherosclerotic cardiovascular disease	8
The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	8
Role of sex hormones in cardiovascular diseases	7
ACE2 level as a marker of CVD	7
Publisher Correction: Cellular and molecular pathobiology of heart failure with preserved ejection fraction	7
Uncertainties about left ventricular thrombus after STEMI	7
Improved gut microbiota profile in individuals with obesity taking statins	7
Travelling with heart failure: risk assessment and practical recommendations	7
Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine	6
Invention and uptake of TAVI over the first 20 years	6
Cardiovascular health concerns in sexual and gender minority populations	6
Very high HDL-C levels are associated with higher mortality in patients with CAD	6
Guidelines to lower intake of added sugar are necessary and justified	6
Myocardial injury in patients with COVID-19	6
Macrophages and neutrophils modulate arrhythmia risk after myocardial infarction	6
AIMing 2 treat atherosclerosis	6
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	6
Collateral cardiovascular damage during the COVID-19 pandemic	6
Cardiac splicing as a diagnostic and therapeutic target	6
Current concepts and novel targets for antiplatelet therapy	6
A roadmap of strategies to support cardiovascular researchers: from policy to practice	6
Exosome-derived microRNAs improve cardiac function	5
Empagliflozin improves outcomes in HFrEF regardless of diabetic status	5
Preventing cardiac damage in patients with COVID-19	5
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	5
The bidirectional association between atrial fibrillation and myocardial infarction	5
Electron microscopy of cardiac 3D nanodynamics: form, function, future	5
Universal flu vaccines: a shot at lifelong cardioprotection?	5
Publisher Correction: Reappraising the role of inflammation in heart failure	5
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	5
Cybersecurity and cardiac implantable electronic devices	5
Detection of subclinical hypertrophic cardiomyopathy	5
Complexity and plasticity of cardiac cellular composition	5
Shaping the future of cardiovascular medicine in the new era of wearable devices	5
A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease	5
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	5
A call for training programmes in cardiovascular genomics	4
Exosomes improve myocardial recovery after infarction	4
Statins promote efferocytosis in atherosclerotic plaques	4
Cardiovascular effects of electronic cigarettes	4
Promising anti-IL-6 therapy for atherosclerosis	4
Diversity in human genetics studies accelerates discovery and improves health care	4
Carotid stenosis management: time to address the misconceptions (‘furphies’)	4
Machine learning predicts risk in ACS	4
Oxidized phospholipids in cardiovascular disease	4
Clopidogrel is a favourable alternative to ticagrelor in older patients with NSTE-ACS	4
FGF23 and klotho at the intersection of kidney and cardiovascular disease	4
Safety of paclitaxel-coated devices in peripheral artery disease	4
A phoenix rises from the ashes of cardiac cell therapy	4
Publisher Correction: Cardiac involvement in the long-term implications of COVID-19	4
Human susceptibility to coronary artery disease: lessons from chimpanzee resilience	4
Twice-yearly inclisiran injections halve LDL-cholesterol levels	4
Heart transplantation: advances in expanding the donor pool and xenotransplantation	4
Lipoprotein(a), platelet function and cardiovascular disease	4
Caffeine consumption and cardiovascular health	4
Boosting mitochondrial metabolism with dietary supplements in heart failure	4
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease	4
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved	3
Targeted therapies for cardiac diseases	3
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction	3
Reply to ‘Mechanisms of ryanodine receptor 2 dysfunction in heart failure’	3
Macrophages promote endothelial-to-mesenchymal transition after MI	3
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	3
Anti-IL-1β therapy lowers leukocyte supply and uptake in atherosclerosis	3